These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31560979)

  • 1. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab.
    Nagata M; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Sugiura K; Tada Y
    J Am Acad Dermatol; 2020 Mar; 82(3):758-761. PubMed ID: 31560979
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remarkable response to ixekizumab in a patient with generalized pustular psoriasis: a therapeutic challenge.
    Hsu HH; Wang HJ; Sun Y; Lan CC
    Ital J Dermatol Venerol; 2024 Jun; 159(3):373-374. PubMed ID: 38635325
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of erythrodermic psoriasis successfully treated with ixekizumab.
    Megna M; Gallo L; Balato N; Balato A
    Dermatol Ther; 2019 Mar; 32(2):e12825. PubMed ID: 30650216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful response of genital psoriasis to ixekizumab: report of six cases.
    García-Legaz Martínez M; Martínez-Doménech Á; Hernández-Bel P; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Sánchez-Carazo JL; Alegre-de Miquel V; Pérez-Ferriols A
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e325-e327. PubMed ID: 30980763
    [No Abstract]   [Full Text] [Related]  

  • 8. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
    Azevedo A; Torres T
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e338-e341. PubMed ID: 31001858
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of acrodermatitis continua of hallopeau with ixekizumab.
    Miller AC; Holland TE; Cohen DJ
    J Dermatolog Treat; 2021 Feb; 32(1):117-119. PubMed ID: 31184530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 18. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pustular psoriasis with severe liver dysfunction: psoriasis-specific immune hepatitis?
    Yamazaki Y; Matsuo S; Ishikawa T; Munetsugu T; Nishizawa A; Fujimoto N; Satoh T
    Eur J Dermatol; 2021 Apr; 31(2):277-279. PubMed ID: 32301714
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis.
    Yosipovitch G; Dong Y; Burge R; Zhu B; Shrom D; Kimball AB
    Acta Derm Venereol; 2019 Oct; 99(11):1031-1032. PubMed ID: 31290556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.